Nov. 5, 2024

NCC will initiate new research to develop a nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for cancer patients.

Sep. 20, 2024

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval

Sep. 17, 2024

SCRUM-Japan GOZILA Confirms Extended Survival with Personalized Cancer Treatment in 4,000+ Patients Study

Sep. 17, 2024

CIRCULATE-Japan GALAXY Confirms Effectiveness of Liquid Biopsy in Predicting Recurrence Risk and Post-operative Treatment Efficacy in Colorectal Cancer

Sep. 12, 2024

Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)